What Cell Microsystems does

Cell Microsystems, Inc. is a Durham, North Carolina-based biotechnology company (incorporated in Delaware; founded 2010) that develops, manufactures, and markets instruments and consumables for single-cell biology, 2D/3D cell culture, shear flow analysis, automated electrophysiology, and cell counting. Its portfolio includes the CellRaft AIR System (single-cell isolation and clone generation using proprietary microscale polystyrene arrays and a fluidics-free glass transfer wand), BioFlux Systems (microfluidic shear flow with 0-200 dyn/cm² control), IonFlux Mercury (automated patch clamp with 16-256 parallel channels), CERO 3D (low-shear bioreactor for organoids/spheroids), CASY Cell Counter & Analyzer (Electronic Current Exclusion technology, GMP/GLP compliant with optional 21 CFR Part 11 module), and TIGR Tissue Grinder. The 2023 acquisition of Fluxion Biosciences added IsoFlux and expanded the BioFlux and IonFlux footprints. Underlying technology integrates proprietary hardware, single-use arrays/plates, and software (CellRaft Cytometry) with AI-assisted image-based verification of monoclonality and phenotypic selection.

The company monetizes through three streams: capital equipment (instruments sold via direct enterprise field sales with quote-based pricing), recurring consumables (CellRaft Arrays, BioFlux Plates, CERO and CASY consumables sold through a public e-commerce storefront with unit pricing from ~$200 to ~$2,750), and contract lab services (cell line development, 3D organoid generation, shear flow assays, and whole-cell patch clamp). GTM combines direct enterprise sales to academic and biopharma buyers (Request Quote/Demo CTAs) with self-serve e-commerce for consumables and lab services as an outsourced-evaluation pathway. Customer base spans academic institutions (UNC Chapel Hill, Duke, Harvard, Stanford, Johns Hopkins, Columbia, Max Planck, Carnegie Mellon, Penn, Albert Einstein, Washington University, Georgia State) and biopharmaceutical firms (Pfizer, Sanofi, Kite Pharma, Colossal Biosciences, an undisclosed Top 10 Global Biopharma).

Cell Microsystems has raised approximately $30 million across disclosed rounds since inception, including ~$12.7 million in November 2021 and ~$6.5 million in August 2023 (led by Telegraph Hill Partners per the funding ledger), with NIH and SBIR non-dilutive funding earlier. Headcount is reported at 11-50 employees, suggesting an established but still scale-stage private company that is reinvesting to broaden its product surface, grow international distribution (via the February 2024 OMNI Life Science alliance for 3D cell culture in North America), and integrate the Fluxion acquisition.

Name

Cell Microsystems

Legal name

Cell Microsystems, Inc.

Website

https://cellmicrosystems.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Cell Microsystems is a Durham, NC-based private biotechnology company that develops and sells instruments, consumables, and lab services for single-cell isolation, 3D cell culture, shear flow analysis, automated patch clamp, and cell counting, serving academic research institutions and biopharmaceutical companies worldwide.

Ownership category

akta.pro rank

Product category

Cell Biology Research Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Analytical Instruments (3826), Laboratory Apparatus & Furniture (3821), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG)

akta.pro secondary industries

General Lab Equipment (Centrifuges, Incubators, Shakers, Ovens) (HLAGAIAC), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• Single-cell isolation
• Automated patch clamp
• 3D cell culture
• Shear flow analysis
• Cell biology instruments

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Scientific Instruments: Sale of capital equipment instruments including CellRaft AIR System, IonFlux Mercury, BioFlux Systems, CERO 3D, CASY Cell Counter, and TIGR Tissue Grinder. Instruments represent high-value capital purchases with typical enterprise sales cycles involving demos and quotes.
2. Consumables: Recurring revenue from consumable products including CellRaft Arrays, BioFlux Plates, CERO Consumables (tubes, plates, solutions), and CASY Consumables (cups, ton, clean, blue solutions). Consumables are repurchased with each experiment or on regular intervals.
3. Lab Services: Contract research services including cell line development, antibody services, 3D organoid generation and screening, shear flow experiments, and whole-cell patch clamp testing. Services provide project-based revenue and help drive instrument adoption.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Cell Microsystems develops, manufactures, and markets integrated instrument platforms and consumables for cell biology research, including the CellRaft AIR System for single-cell isolation and clone generation, BioFlux shear flow systems, IonFlux Mercury automated patch clamp systems, CERO 3D incubators and bioreactors, the CASY cell counter and analyzer, and the TIGR tissue grinder. The company also sells proprietary consumables (CellRaft Arrays, BioFlux Plates, CERO and CASY consumables), optimized mCells ion channel cell lines, and contract research lab services supporting cell line development, organoid generation, and electrophysiology studies.

Product overview

Cell Microsystems offers a platform of cell engineering, culture, and analysis instruments designed for research and drug discovery applications. The core product lineup includes the CellRaft AIR System (single cell isolation and clone generation), BioFlux Systems (shear flow for physiological conditions), IonFlux Mercury Systems (automated patch clamp electrophysiology), CERO 3D (3D cell culture and bioreactor), CASY Cell Counter & Analyzer, and TIGR Tissue Grinder. The company also provides associated consumables (CellRaft Arrays, BioFlux Plates, CERO/CASY Consumables), optimized cell lines (mCells), and contract research lab services. Following the 2023 acquisition of Fluxion Biosciences, the portfolio expanded to include IsoFlux systems. Products integrate across 2D/3D cell biology, gene editing, genomics, stem cell research, and ion channel analysis workflows.

Differentiator

Problem solved

Functional benefit

Brands

• IonFlux Mercury: Automated patch clamp system for ion channel research and drug discovery
• CellRaft AIR
• BioFlux
• CERO 3D
• TIGR
• CASY

Products and services

• CellRaft AIR System Integrated platform for imaging, identifying, and isolating viable single cells, colonies, or organoids using proprietary CellRaft Arrays and CellRaft Cytometry software; maintains cells in shared-media flask-like conditions with image-verified monoclonality for cell line development, gene editing, stem cell, and organoid workflows.
• BioFlux Systems (BioFlux 200+ and BioFlux 1000HT) Microfluidic shear flow systems that introduce physiological shear stress (0-200 dyn/cm²) to cell biology and microbiology experiments, with dual microenvironments, pulsatile flow capability, and high-throughput imaging of up to 24 experiments per plate for emulating in vivo conditions.
• IonFlux Mercury Systems Automated patch clamp systems providing 16 to 256 parallel channel recordings for high-throughput electrophysiology, with fast liquid exchange, continuous solution flow, and temperature control up to 40°C; offers one of the lowest costs per data point in the industry for ion channel drug discovery.
• CERO 3D Incubator & Bioreactor 3D cell culture technology for organoid, spheroid, stem cell, and tissue research, featuring low-shear bi-directional rotation with precise automated control of CO2, temperature, and pH for long-term culture, expansion, and differentiation.
• CASY Cell Counter & Analyzer Cell counting and analysis instrument using Electronic Current Exclusion (ECE) and Pulse Field Analysis technology to provide precise cell counts and viability assessments without dyes or reagents; GMP/GLP compliant with optional 21 CFR Part 11 module for regulated environments.
• TIGR Tissue Grinder and Dissociator Semi-automated benchtop tissue dissociation system using gentle mechanical rotor-stator grinding to yield high-quality single cells rapidly and reproducibly; processes four individual samples in parallel and is 5-15x faster than enzymatic methods with high cell viability.
• IsoFlux System Automated cell-based assay tool acquired from Fluxion Biosciences, expanding Cell Microsystems' offerings for cellular analysis and circulating tumor cell research applications.
• CellRaft Arrays Microwell arrays (Quad Reservoir and Single Reservoir formats) containing thousands of CellRafts for spatial segregation, imaging, and isolation of single cells, monoclonal colonies, or 3D cultures when used with the CellRaft AIR System.
• BioFlux Plates (BioFlux 200+ and BioFlux 1000HT) Specialized microfluidic plates (BioFlux 200+ and BioFlux 1000HT) for shear flow experiments, available in 24-well and 48-well formats with low-shear, high-shear, and custom substrate configurations for use with BioFlux Systems.
• CERO Consumables (CEROTubes, CEROsolution1, CEROplates) Consumables including CEROTubes (48 units), CEROsolution1 (4x10ml), 96well CEROplate (24 plates), and 384well CEROplate (24 plates) for use with the CERO 3D Incubator & Bioreactor.
• CASY Consumables (CASY ton, cups, clean, blue) Consumables for the CASY Cell Counter & Analyzer including CASY ton (10-liter container), CASY cups (1,800 cups), CASY clean (500ml), and CASY blue (30ml) reagents.
• mCells (Ion Channel-Optimized Cell Lines) Ion channel-optimized cell lines expressed in HEK-293 cells for use with IonFlux Mercury automated patch clamp systems; available channels include GABA A variants (α1β2γ2L, α2β2γ2L, α3β2γ2L).
• Cell Line Development Services Contract research services utilizing CellRaft technology to generate gene-edited cell lines from challenging or rare cell types with results in weeks, including image-based validation and phenotypic screening.
• 3D Organoid Generation and Screening Services Matrix-based or bioreactor-based 3D cell culture services for reproducible assays using CellRaft and CERO 3D technologies.
• Shear Flow Assay Services Contract research services using BioFlux Shear Flow Systems for platelet adhesion and cell invasion assays under physiological conditions.
• Whole-Cell Patch Clamp Services IonFlux automated patch clamp laboratory services for high-throughput electrophysiology recordings, including use of validated mCells for ion channel testing.

Quantifiable outcome

• 10-50X increase in viable monoclonal colonies compared to limiting dilution
• +5 more outcomes

Named customers17 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

One partnership is on record.

• OMNI Life SciencecoreStrategic or Co-development Partner · 1 February 2024In February 2024, US-based Cell Microsystems formed a strategic alliance with Germany-based OMNI Life Science to introduce three 3D cell culture products in North America. This partnership enables Cell Microsystems to expand distribution of its CERO 3D and related 3D cell culture technology through OMNI Life Science's established network in the North American market.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cytena (BICO Group): Cytena's single-cell cloning systems (c.sight and Cellenc) directly compete with CellRaft AIR for clonal cell line development workflows in pharma and cell therapy. Both address image-based verification of monoclonality and are sold into the same biopharma and academic accounts.
• Molecular Devices (Danaher): Molecular Devices offers automated patch clamp platforms (e.g., PatchXpress, OpusXpress, and higher-throughput systems) that compete directly with IonFlux Mercury in ion channel screening and drug discovery workflows for biopharma.
• Nanion Technologies: Nanion's automated patch clamp and bilayer electrophysiology systems (Port-a-Patch, SyncroPatch, Patchliner) compete with IonFlux Mercury in cardiac safety, ion channel research, and drug discovery markets.
• Sony Biotechnology: Sony Biotechnology's cell sorters (e.g., MA900, SH800) compete with BD and represent an incumbent option for fluorescence-activated single-cell isolation, an alternative approach to CellRaft's image-based isolation in cell line development workflows.
• Beckman Coulter Life Sciences (Danaher): Beckman Coulter's Vi-Cell cell viability analyzers compete directly with the CASY Cell Counter & Analyzer in research and GMP cell counting applications across pharma and academic labs.
• Mimetas: Mimetas' OrganoPlate 3D cell culture platforms compete with the CERO 3D Incubator & Bioreactor for organoid, spheroid, and organ-on-chip drug screening applications in academic and biopharma research.
• InSphero: InSphero provides 3D InSight microtissue platforms and organoid services that compete with CERO 3D-based workflows for disease modeling and drug discovery, serving overlapping biopharma and academic customers.

Broad incumbents

• BD Biosciences (Becton Dickinson): BD's FACSDiscover and cell sorter families are the incumbent alternative to CellRaft for single-cell isolation and cloning. BD offers broad flow cytometry, cell sorting, and reagent portfolios used by the same academic and biopharma customers.
• 10x Genomics: 10x Genomics' Chromium single-cell platforms target genomic and transcriptomic single-cell analysis rather than clonal isolation, but they compete for the same single-cell biology budget and customer relationships within academic and biopharma labs.
• Thermo Fisher Scientific: Thermo Fisher's broad lab instruments and cell biology portfolio (cell culture, cell counting, imaging, and cell line development tools) overlaps with several Cell Microsystems product lines and serves the same academic, biopharma, and CRO customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cellmicrosystems
• Xx.com/CellMicrosys

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cell Microsystems